Cumulative life course impairment: Identifying patients at risk

Current Problems in Dermatology (Switzerland)

Volumn 44, Issue , 2013, Pages 74-81

  Augustin, Matthias ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC DISEASE; CHRONICITY; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; HUMAN; LIFE; MOOD; PREDICTOR VARIABLE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RISK ASSESSMENT; SKIN DISEASE; SOCIAL SUPPORT; STIGMA; CONCEPTUAL FRAMEWORK; COPING BEHAVIOR; CUMULATIVE LIFE COURSE IMPAIRMENT; PATIENT ATTITUDE; PERSONALITY; PROFESSIONAL IMAGE; RISK REDUCTION;

ADAPTATION, PSYCHOLOGICAL; CHRONIC DISEASE; COMORBIDITY; COST OF ILLNESS; HUMANS; LONGEVITY; PERSONALITY; QUALITY OF LIFE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; SOCIAL SUPPORT;

EID: 84928490503     PISSN: 14215721     EISSN: 16622944     Source Type: Book Series    
DOI: 10.1159/00035055555     Document Type: Article

References (55)

1. Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M: Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 989-1004.
2. Warren RB, Kleyn CE, Gulliver WP: Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol 2011; 164(suppl 1): 1-14.
3. Offidani E, Tomba E, Linder MD : Two key concepts in the life course approach in medicine: allostatic load and cumulative life course impairment; Linder MD, Kimball AB (eds): Dermatological Diseases and Cumulative Life Course Impairment. Curr Probl Dermatol. Basel, Karger, 2013, vol 44, pp 17-32.
4. Fredriksson T, Pettersson U: Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359. Dermatologica 1979; 158: 60-64.
5. Weisman S, Pollack CR, Gottschalk RW: Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatol Treat 2003; 14: 158-165.
6. Langley RG, Ellis CN: Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51: 563-569.
7. Augustin M, Ogilvie A: Methods of outcomes measurement in nail psoriasis. Dermatology 2010; 221(suppl 1): 23-28.
8. Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke MA: Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163: 580-585.
9. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K: Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter crosssectional study in Germany. Dermatology 2008; 216: 366-372.
10. Reimus JL, Vingerhoets AJ, Soons PH, Korstanje MJ: Suffering in psoriasis patients: its relation with illness severity and subjective well-being. Int J Dermatol 2007; 46: 1042-1045.
11. Krenzer S, Radtke M, Schmitt-Rau K, Augustin M: Characterization of patient-reported outcomes in moderate to severe psoriasis. Dermatology 2011; 223: 80-86.
12. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y: The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-392.
13. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N: Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10. Epub 2010 Sep 21.
14. Baker CS, Foley PA, Braue A: Psoriasis uncovered - measuring burden of disease impact in a survey of Australians with psoriasis. Aust J Dermatol 2013; 54(suppl 1): 1-6.
15. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mørk C, Sigurgeirsson B: Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002; 146: 1006-1016.
16. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schaefer I: Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 633-636.
17. Chiam LY, de Jager ME, Giam YC, de Jong EM, van de Kerkhof PC, Seyger MM: Juvenile psoriasis in European and Asian children: similarities and differences. Br J Dermatol 2011; 164: 1101-1103
18. De Jager ME, de Jong EM, van de Kerkhof PC, Evers AW, Seyger MM: An intrapatient comparison of quality of life in psoriasis in childhood and adulthood. J Eur Acad Dermatol Venereol 2011;25: 828-831.
19. Varni JW, Globe DR, Gandra SR, Harrison DJ, Hooper M, Baumgartner S: Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr 2012; 171: 485-492. Epub 2011 Sep 30.
20. Hrehorów E, Salomon J, Matusiak L, Reich A, Szepietowski JC: Patients with psoriasis feel stigmatized. Acta Derm Venereol 2012; 92: 67-72.
21. Schmid-Ott G, Schallmayer S, Callies IT: Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol 2007; 25: 547-554.
22. Schmid-Ott G, Künsebeck HW, Jäger B, Sittig U, Hofste N, Ott R, Malewski P, Lamprecht F: Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 2005; 85: 27-32.
23. Janowski K, Steuden S, Pietrzak A, Krasowska D, Kaczmarek L, Gradus I, Chodorowska G: Social support and adaptation to the disease in men and women with psoriasis. Arch Dermatol Res 2012; 304: 421-432.
24. Schneider G, Heuft G, Hockmann J: Determinants of social anxiety and social avoidance in psoriasis outpatients. J Eur Acad Dermatol Venereol 2011. doi: 10.1111/j.1468-3083.2011.04307.x, epub ahead of print.
25. Augustin M, Lange S, Wenninger K, Seidenglanz K, Amon U, Zschocke I: Validation of a Comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system. Eur J Dermatol 2004; 107-113.
26. Dominguez PL, Han J, Li T, Ascherio A, Qureshi AA: Depression and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol 2012.
27. Spielberger CD, Gorusch RL, Lushene PL: Manual for the State-Trait Anxiety Inventory. Palo Alto, Consulting Psychologist Press, 1970.
28. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
29. Herrmann C: International experiences with the hospital anxiety and depression scale - a review of validation data and clinical results. J Psychosom Res 1997; 42: 17-41.
30. Miniszewska J, Juczyński Z, Ograczyk A, Zalewska A: Health-related quality of life in psoriasis: important role of personal resources. Acta Derm Venereol 2013. doi: 10.2340/00015555-1530, epub ahead of print.
31. Fortune DG, Richards HL, Main CJ, Griffiths CE: Patients' strategies for coping with psoriasis. Clin Exp Dermatol 2002; 27: 177-184.
32. Muthny FA: FKV, Freiburger Fragebogen zur Krankheitsverarbeitung. Freiburg Questionnaires on Coping with Illness. Weinheim, Beltz, 1989.
33. Lazarus RS, Folkman S: Stress, Appraisal and Coping. New York, Springer, 1984.
34. Lange S, Zschocke I, Seidenglanz K, Schiffler A, Zöllinger A, Amon U, Augustin M: Predictors of the quality of life in a patient with atopic dermatitis. Dermatol Psychosom 2000; 1: 66-70.
35. Blome C, Simianer S, Purwins S, Laass A, Rustenbach SJ, Schäfer I, Radtke M, Augustin M: Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 2010; 221: 154-159.
36. Finlay AY, Kahn GK: Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
37. Chren MM, Sasek RJ, Flocke SA, Zyzanski SZ: Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-1440.
38. Linder D, Sampogna F, Torreggiani A, Balato N, Bianchi L, Cassano N, Conti A, Gisondi P, Musumeci ML, Piaserico S, Potenza C, Romano GV, di Luzio Paparatti U: Psodisk, a new visual method for assessing the burden of psoriasis on patients, J Eur Acad Dermatol 2012: 1163-1166.
39. Altobelli E, Petrocelli R, Maccarone M, Altomare G, Argenziano G, Giannetti A, Peserico A, Vena GA, Tiberti S, Chimenti S, Peris K: Risk factors of hypertension, diabetes and obesity in Italian psoriasis patients: a survey on socio-demographic characteristics, smoking habits and alcohol consumption. Eur J Dermatol 2009; 19: 252-256.
40. Setty AR, Curhan G, Choi HK: Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 2007; 120: 953-959.
41. Qureshi AA, Dominguez PL, Choi HK, Han J, Curhan G: Alcohol intake and risk of incident psoriasis in US women: a prospective study. Arch Dermatol 2010; 146: 1364-1369.
42. Setty AR, Curhan G, Choi HK: Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007; 167: 1670-1675.
43. Sterry W, Strober BE, Menter A, International Psoriasis Council: Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649-655.
44. Neimann AL, Shin DB, Wang X, et al: Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
45. Cohen AD, Sherf M, Vidavsky L, et al: Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-155.
46. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
47. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al: Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-276.
48. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, Stahle-Bäckdahl M: Increased risk of cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230.
49. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al: The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499.
50. Kimball AB, Galdman G, et al: National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-1042.
51. Daudén E, Castañeda S, Suárez C, García- Campayo J, Blasco AJ, Aguilar MD, Ferrándiz C, Puig L, Sánchez- Carazo JL, Working Group on Comorbidity in Psoriasis: Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 2012, doi 10.1111/ jdv.12024, epub ahead of print.
52. Augustin M, Langenbruch AK, Gutknecht M, Radtke MA, Blome C: Quality of Life Measures for Dermatology: Definition, Evaluation, and Interpretation. Current Dermatology Report. Berlin, Springer, 2012.
53. Prinsen CA, de Korte J, Augustin M, Sampogna F, Salek SS, Basra MK, Holm EA, Nijsten TE: EADV Taskforce on Quality of Life: Measurement of healthrelated quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. J Eur Acad Dermatol Venereol 2013, doi: 10.1111/jdv.12090, epub ahead of print.
54. Robitaille A, Orpana H, McIntosh CN: Psychometric properties, factorial structure, and measurement invariance of the English and French versions of the Medical Outcomes Study social support scale. Health Rep 2011; 22: 33-40.
55. Wendt A, Petermann F: Measuring scales for assessment of coping behavior: a critical evaluation. Z Klin Psychol Psychiatr Psychother 1996; 44: 3-32.